Article Citations

(Scroll Down for More)

Clinical TrialsCore FacilitiesLab ProtocolsPoliciesProposalsPublicationsTrialShareStrategic Plans

Grass Pollen Immunotherapy plus Dupilumab for Tolerance Induction

Principal Investigator

Stephen Durham | Imperial College London | London, England

Locations

Imperial College School of Medicine: National Heart and Lung Institute, Section for Allergy and Clin | London,

Study Code

ITN084AD

Study Status

Follow-up

Abstract

GRADUATE is a clinical research trial, which will test whether a novel drug called Dupixent® given with grass pollen immunotherapy will help the immunotherapy work in a shorter treatment period and remain effective after the completion of treatment. Immunotherapy reduces symptoms of hay fever and modifies the allergic disease by increasing tolerance to the grass pollen.

We want to hear from volunteers at any time of year.

Participants in the GRADUATE study will be asked to start treatment a while before the hay fever season begins, and will be randomly assigned to one of three groups who will be given:

  • Grazax® plus Dupixent®
  • Grazax® plus placebo (an inactive substance made to look like the study drug)
  • placebo plus placebo

The total study length is 3 years. The study visits are summarized below:

Treatment Period 2 years Visits every 4 weeks to provide treatment and monitor general health and hayfever symptoms
Follow-up Period 1 year Monthly phone calls and 5 visits throughout the year to check on progress

‍

If eligible, participants will receive medical advice about their hay fever and rescue medications (like antihistamines and nasal sprays) in season as needed, as well as compensation for expenses.

Qualification

[Clinicaltrials.gov][Study Website]

Articles

Download Citations